A Deeper Dive into NASH Diagnosis and Treatment: An Augmented Reality Experience
Premiere Date: Tuesday, April 28, 2020This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, April 28, 2021
Note: Credit Is No Longer Available
 | Mazen Noureddin, MD, MHSc Director, Fatty Liver Program Karsh Division of Gastroenterology and Hepatology Comprehensive Transplant Center Cedars-Sinai Medical Center Los Angeles, CA |
 | Scott C. Howell, DO AIDS Healthcare Foundation Los Angeles, CA |
 | Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD, President, Inova Medicine Services Chairman, Clinical Research, Inova Health System Professor and Chairman of Department of Medicine Inova Fairfax Medical Campus Falls Church, VA |
Obesity and diabetes are on the rise, leading to an increased prevalence of non-alcoholic fatty liver disease (NAFLD), which in some cases may progress to non-alcoholic steatohepatitis (NASH). NAFLD affects approximately 30% of the U.S. population, with NASH effecting about 5%. NASH comes with a significant risk of progression to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma. Disease models project that the number of individuals with end-stage liver disease will double - or possibly triple - by 2030.
With the majority of high-risk patients first seen in the primary care setting, it is imperative that internists and primary care physicians identify patients at risk for NASH. Although liver biopsy was previously the best test for identifying the critical endpoints of NASH, several noninvasive, yet effective, tests have been developed recently that have the potential to be implemented in primary care settings. While currently there are no approved treatments for NASH, novel targeted therapies are being studied in phase III clinical trials, some of which have shown promising results.
In this CME Outfitters virtual symposium, expert faculty utilize Augmented Reality to visually dive into NASH, with particular focus on risk stratification, diagnosis, and emerging targeted therapies.
At the end of this CE activity, participants should be able to:
- Identify risk factors associated with NAFLD and NASH.
- Utilize appropriate noninvasive tests for the identification of NASH in patients with NAFLD.
- Evaluate novel therapeutic targets and clinical evidence on emerging therapies for NASH.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify risk factors associated with NAFLD and NASH.
- Describe appropriate noninvasive tests for the identification of NASH in patients with NAFLD.
- Evaluate novel therapeutic targets and clinical evidence on emerging therapies for NASH.
Supported by an educational grant from Intercept Pharmaceuticals, Inc.
Internists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number:
Enduring: 0376-0000-20-080-H01-P
Type: knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring material
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Noureddin reports that he receives research support from Allergan; Bristol-Myers Squibb Company; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Galectin Therapeutics Inc.; Galmed Pharmaceuticals; GENFIT; Gilead Sciences, Inc.; Novartis; Shire and Zydus Pharmaceuticals, Inc. He is on the advisory board or speakers bureau for Abbott; Allergan; Blade Therapeutics; Echosens North America; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novartis; OWL; Pfizer Inc.; Roche Diagnostics, North America; and Siemens. He is a stock shareholder (directly purchased) of Ananetos and Viking Therapeutics, Inc.
Dr. Howell reports he is a consultant for Echosens and Semler Scientific, Inc.
Dr. Younossi reports that he receives research support from Bristol-Myers Squibb Company; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc. He is a consultant for Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novo Nordisk; Siemens; Terns Pharmaceuticals, Inc.; and Viking Therapeutics, Inc.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-099-042820-60
